ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.
Abstract readPublished Erratum
In one paragraph
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Prognostic significance and pathogenesis of RFC3 gene expression in diffuse large B-cell lymphoma.PeerJ · 2025Article
- Construction of a PANoptosis-related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Ovarian Cancer.Current medicinal chemistry · 2025Article
- Advances in biology, diagnosis and treatment of DLBCL.Annals of hematology · 2024Review
- Identification of cuproptosis-related gene clusters and immune cell infiltration in major burns based on machine learning models and experimental validation.Frontiers in immunology · 2024Article
- IdentifyingPeerJ · 2023Article
- Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities.Journal of hematology & oncology · 2021Review
- Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.Journal of cancer research and clinical oncology · 2021Article
- An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.Journal of immunology research · 2021Article
- Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.EBioMedicine · 2020Article
Corrections and comments
- Erratum for
Authors and funding
39 authors.
S CiavarellaHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
M C VeglianteHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
M FabbriDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
S De SummaMolecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
F MelleDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
G MottaDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
V De IuliisPost-graduated Medical School of Clinical Pathology, "Gabriele D'Annunzio", University of Chieti, Chieti.
G OpintoFunctional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
A EnjuanesUnitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain.
S RegaPathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
A GulinoTumor Immunology Unit, Dipartimento per la Promozione della Salute e Materno Infantile "G. D'Alessandro", University of Palermo, Palermo.
C AgostinelliDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna.
A ScattonePathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
S TommasiMolecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
A MangiaFunctional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
F MelePathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
G SimonePathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
A F ZitoPathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
G IngravalloPathology Section, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", Bari.
U VitoloDepartment of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino.
A ChiappellaDepartment of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino.
C TarellaOnco-Hematology Unit, European Institute of Oncology, IRCCS, Milan.
A M GianniOnco-Hematology Unit, European Institute of Oncology, IRCCS, Milan.
A RambaldiDepartment of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; School of Medicine, University of Milan, Milan, Italy.
P L ZinzaniDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna.
B CasadeiDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna.
E DerenziniOnco-Hematology Unit, European Institute of Oncology, IRCCS, Milan.
G LosetoHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
A PileriDepartment of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna.
V TabanelliDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
S FioriDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
A Rivas-DelgadoCIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain.
A López-GuillermoCIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain.
T VenesioCandiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy.
A SapinoCandiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy; Department of Medical Sciences, University of Torino, Turin, Italy.
E CampoCIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona; University of Barcelona, Barcelona, Spain.
C TripodoPathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
A GuariniHematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari.
S A PileriDivision of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.